Navelbine (Vinorelbine)

Vinorelbine binds to tubulin, a protein essential for microtubule formation. By preventing microtubule polymerisation, it disrupts the mitotic spindle, causing cell‑cycle arrest in the M‑phase and leading to apoptosis of rapidly dividing cancer cells.

The specific dose of Navelbine is determined by the prescribing oncologist based on the patient’s diagnosis, body surface area, renal and hepatic function, and treatment protocol. Dosage adjustments are made individually and should follow the prescriber’s instructions.

Vinorelbine is classified as potentially teratogenic, and its safety in pregnancy has not been established. Women of child‑bearing potential should use effective contraception during treatment and for a period after the last dose. Breastfeeding is not recommended while on therapy.

To request Navelbine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Vinorelbine belongs to the Vinca alkaloid class, which differs from taxanes or platinum‑based agents in its mechanism of tubulin inhibition. Compared with taxanes, vinorelbine often has a distinct toxicity profile, with less neuropathy but a higher incidence of neutropenia. Choice of therapy depends on disease stage, prior treatments, and patient tolerance.

Navelbine capsules should be stored at ambient temperature, below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and store out of reach of children.

Navelbine is supplied as oral capsules that are taken by mouth with water, usually on an empty stomach. The exact timing relative to meals and other chemotherapy agents is determined by the treating physician and the specific treatment protocol.

The most serious risks include severe neutropenia that can lead to life‑threatening infections, pulmonary toxicity such as interstitial pneumonitis, and rare but severe allergic reactions. Patients should be monitored closely for signs of infection, respiratory difficulty, or hypersensitivity.

Vinorelbine is contraindicated in patients with known hypersensitivity to vinorelbine or other Vinca alkaloids, those with severe bone‑marrow suppression, and individuals with uncontrolled severe pulmonary disease. Caution is also advised for patients taking strong CYP3A4 inhibitors or other myelosuppressive drugs.